Anne Floquet is an expert in Oncology at Institut Bergonié (France). As of October 2026, ScienceLeadR ranks Anne Floquet in the top 1% of experts worldwide for Ovarian Neoplasms, Adnexal Diseases and Gonadal Disorders. Anne Floquet has authored 260 publications, the most recent in 2024, and is an investigator in 28 clinical trials. SLR score: 911 (community average: 125). How the SLR is computed.

LeadR Profile

Anne Floquet Institut Bergonié France
911 ScienceLeadR Reputation 911
Network Map

Oncology

Subspecialties: Genetics - Gynecology - Endocrinology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1996 - 2024

Source: PubMed

Institut Bergonié

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 260

Citations

Citations: 17 499 1st author: 6 Last author: 9 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
PMID 39528049 — poly(adp-ribose) polymerases, neoplasms, disease progression, bevacizumab, poly adenosine diphosphate ribose, drug therapy, maintenance, ovarian neoplasms, therapeutics, chemotherapy
Ann Oncol Top journal20244
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
PMID 38834579 — biological science disciplines, ovarian neoplasms, bevacizumab
Nat Commun20240
Genomic profile analysis of leiomyomas with bizarre nuclei and fumarate hydratase deficient leiomyomas: Strengths, weaknesses, and limitations of array-CGH interpretation.
PMID 38481055 — genes, cell transformation, neoplastic, neoplasms, fumarates, chromosome aberrations, leiomyoma, fumarate hydratase
Genes Chromosomes Cancer20246
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
PMID 38443333 — safety, biological science disciplines, ovary, neoplasms, bevacizumab, ovarian neoplasms, therapeutics
Nat Commun202426
HE4 and CA-125 kinetics to predict outcome in patients with recurrent epithelial ovarian carcinoma: the META4 clinical trial.
PMID 38273857 — ovary, ovarian neoplasms, carcinoma, ovarian epithelial
Front Oncol20244

Clinical Studies 28

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 2 11
Phase 3 11
N/A 3
Phase 1/Phase 2 3

By status:

Completed 21
Recruiting 3
Active not recruiting 2
Unknown 1
Withdrawn 1

By type:

Interventional 25
Observational 3

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 2
multicentric5to9 2
multicentricup10 21

Main Topics

Cohort/Consortium Investigators 1

LeadR Networks

Main global connection map